Hyper-Activation of STAT3 Sustains Progression of Non-Papillary Basal-Type Bladder Cancer via FOSL1 Regulome

An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers

(2018) Mélanie Mahe et al.   EMBO Molecular Medicine

Targeting the IL-6/JAK/STAT3 signalling axis in cancer

(2018) Daniel E. Johnson et al.   Nature Reviews Clinical Oncology

Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer

(2018) Nagaraj S Nagathihalli et al.   CANCER RESEARCH

EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer

(2018) Li Wang et al.   Nature Communications

Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends

(2017) Sebastien Antoni et al.   EUROPEAN UROLOGY

Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy

(2017) Roland Seiler et al.   EUROPEAN UROLOGY

Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification

(2017) Gottfrid Sjödahl et al.   JOURNAL OF PATHOLOGY

Origins of Bladder Cancer

(2016) Bogdan Czerniak et al.   Annual Review of Pathology-Mechanisms of Disease

Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma

(2016) Jakob Hedegaard et al.   CANCER CELL

FRA1 promotes squamous cell carcinoma growth and metastasis through distinct AKT and c-Jun dependent mechanisms

(2016) Xiaoling Zhang et al.   Oncotarget

Truncating Prolactin Receptor Mutations Promote Tumor Growth in Murine Estrogen Receptor-Alpha Mammary Carcinomas

(2016) Obi L. Griffith et al.   Cell Reports

Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use

(2016) Vipulkumar Dadhania et al.   EBioMedicine

Molecular subtypes of urothelial carcinoma are defined by specific gene regulatory systems

(2015) Pontus Eriksson et al.   BMC Medical Genomics

Aberrantly expressed Fra-1 by IL-6/STAT3 transactivation promotes colorectal cancer aggressiveness through epithelial–mesenchymal transition

(2015) Hong Liu et al.   CARCINOGENESIS

Utility of uroplakin II expression as a marker of urothelial carcinoma

(2015) Wei Tian et al.   HUMAN PATHOLOGY

Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer

(2015) M.-W. Zheng et al.   MOLECULAR CANCER THERAPEUTICS

Targeted therapies in bladder cancer: an overview of in vivo research

(2015) Kim E. M. van Kessel et al.   Nature Reviews Urology

limma powers differential expression analyses for RNA-sequencing and microarray studies

(2015) Matthew E. Ritchie et al.   NUCLEIC ACIDS RESEARCH

Fra-1 is a key driver of colon cancer metastasis and a Fra-1 classifier predicts disease-free survival

(2015) Sedef Iskit et al.   Oncotarget

Functional and molecular characterization of cancer stem-like cells in bladder cancer: a potential signature for muscle-invasive tumors

(2015) Margarida Ferreira-Teixeira et al.   Oncotarget

Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy

(2014) Woonyoung Choi et al.   CANCER CELL

Comprehensive molecular characterization of urothelial bladder carcinoma

(2014)   NATURE

Bladder cancers arise from distinct urothelial sub-populations

(2014) Jason Van Batavia et al.   NATURE CELL BIOLOGY

Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma

(2014) Kunyoo Shin et al.   NATURE CELL BIOLOGY

Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology

(2014) J. S. Damrauer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

voom: precision weights unlock linear model analysis tools for RNA-seq read counts

(2014) Charity W Law et al.   GENOME BIOLOGY

Recent advances in the diagnosis and treatment of bladder cancer

(2013) Grace Cheung et al.   BMC Medicine

Sox2 Cooperates with Inflammation-Mediated Stat3 Activation in the Malignant Transformation of Foregut Basal Progenitor Cells

(2013) Kuancan Liu et al.   Cell Stem Cell

Therapeutic modulators of STAT signalling for human diseases

(2013) Gabriella Miklossy et al.   NATURE REVIEWS DRUG DISCOVERY

IL-6 Expression Regulates Tumorigenicity and Correlates with Prognosis in Bladder Cancer

(2013) Miao-Fen Chen et al.   PLoS One

Stat3 Activation in Urothelial Stem Cells Leads to Direct Progression to Invasive Bladder Cancer

(2012) P. L. Ho et al.   CANCER RESEARCH

A Molecular Taxonomy for Urothelial Carcinoma

(2012) G. Sjodahl et al.   CLINICAL CANCER RESEARCH

Normal and neoplastic urothelial stem cells: getting to the root of the problem

(2012) Philip Levy Ho et al.   Nature Reviews Urology

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Three differentiation states risk-stratify bladder cancer into distinct subtypes

(2012) J.-P. Volkmer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

New Strategies in Muscle-Invasive Bladder Cancer: On the Road to Personalized Medicine

(2011) J. B. Shah et al.   CLINICAL CANCER RESEARCH

Fra-1 controls motility of bladder cancer cells via transcriptional upregulation of the receptor tyrosine kinase AXL

(2011) A E Sayan et al.   ONCOGENE

A scaling normalization method for differential expression analysis of RNA-seq data

(2010) Mark D Robinson et al.   GENOME BIOLOGY